Emricasan is a potent caspase inhibitor primarily investigated for its anti-apoptotic and anti-inflammatory properties. It has been studied in the context of liver diseases, including non-alcoholic steatohepatitis (NASH), liver fibrosis, and cirrhosis, where it helps reduce hepatocyte cell death and inflammation. Emricasan has also shown potential in improving markers of liver function and reducing fibrosis progression in preclinical and clinical trials. Additionally, it has been explored in ischemia-reperfusion injury, particularly during liver transplantation, to protect liver tissue from damage after blood flow is restored. Its ability to modulate cell death pathways makes it a candidate for conditions involving excessive apoptosis, such as acute liver failure and other degenerative diseases.